[Edaily Reporter NA EUN-KYUNG ] MEDIPOST CO., LTD.(078160)continued its growth trend year-over-year, posting consolidated revenue of 57.5 billion won through the third quarter of this year. “Cartistem,” a stem cell therapy for knee osteoarthritis that has been on the market in South Korea for 14 years, has successfully completed Phase 3 clinical trials in Japan and is preparing to apply for marketing authorization. The company is also accelerating its expansion into overseas markets by administering the drug to patients in Phase 3 clinical trials in the United States.
MEDIPOST CO., LTD. announced on the 16th that its cumulative consolidated revenue for the first three quarters of this year reached 57.5 billion won, a 3.1% increase compared to the same period last year. Revenue on a standalone basis was 61.5 billion won. The consolidated operating loss totaled 61.0 billion won, while the standalone operating loss was 800 million won.
The umbilical cord blood banking and stem cell therapy businesses accounted for the lion’s share of revenue. Cumulative third-quarter revenue from the umbilical cord blood banking business totaled 30.1 billion won, representing 52.5% of the total, while the stem cell therapy business generated 13.1 billion won in revenue. Revenue from the health functional food business was 8.1 billion won.
The consolidated operating loss was driven by significant R&D expenditures focused on the clinical trials and regulatory approval preparations for CATIS INC. in the U.S. and Japan. MEDIPOST CO., LTD. explained that while overseas clinical costs have increased, the company is maintaining a stable revenue base through its domestic operations.
CartiStem is a treatment for knee cartilage defects that utilizes allogeneic mesenchymal stem cells extracted from umbilical cord blood. It works by transplanting a combination of stem cells and hyaluronic acid into areas of knee cartilage damaged by degenerative changes or repeated trauma to promote cartilage regeneration. Unlike typical intra-articular injections, it is a surgical treatment applied directly to the damaged cartilage.
Since receiving marketing approval from the Ministry of Food and Drug Safety in January 2012, the product has been commercially available in South Korea. In 2017, annual sales exceeded 10 billion won for the first time, and in 2023, they reached 21.6 billion won, surpassing the 20 billion won mark. As of the end of 2025, cumulative sales are estimated at approximately 169.3 billion won, and the cumulative number of patients treated has exceeded 33,000.
The clinical and prescribing experience accumulated in South Korea is serving as the foundation for overseas expansion. In Japan, the company announced the results of its Phase 3 clinical trial last May, stating that it met all key efficacy endpoints.
The clinical trial, conducted at 13 medical institutions in Japan on 130 patients with knee osteoarthritis, compared the therapeutic effects of Cartistem with those of hyaluronic acid injections. The results showed statistically significant differences compared to the control group in both the improvement rates for the 52-week Knee Pain and Function Assessment (WOMAC) and the Cartilage Damage Grade (ICRS).
Based on these results, MEDIPOST CO., LTD. plans to apply for marketing authorization in Japan within the year and aims to obtain approval by 2027. In December of last year, the company also signed an agreement with Japan’s Teikoku Pharmaceutical for exclusive local distribution rights to CATIS INC. Under this structure, additional technology royalties and revenue from the supply of finished products may be generated depending on the progress of the approval and commercialization phases.
In the United States, the company received approval from the Food and Drug Administration (FDA) for its Phase 3 clinical trial protocol last February and began administering the first dose to a patient in July. The clinical trial is being conducted at approximately 70 medical institutions in the U.S. and Canada, involving 300 patients with knee osteoarthritis.
Notably, MEDIPOST CO., LTD. skipped the U.S. Phase 2 trial and proceeded directly to Phase 3 by leveraging clinical and post-marketing data accumulated in South Korea. The company has also established a development strategy to pursue approval based on a single confirmatory trial, following consultations with the FDA. MEDIPOST CO., LTD. expects this approach to reduce both the number of patients required for the clinical trial and development costs compared to the original plan.
Research to confirm the long-term therapeutic effects of Cartistem is also underway. MEDIPOST CO., LTD. is analyzing long-term follow-up data from patients who have actually received treatment in South Korea and plans to release interim results from real-world evidence (RWE) studies within the year. The company plans to use this data in overseas regulatory approvals and health insurance reimbursement negotiations as well.
MEDIPOST CO., LTD. reorganized its management structure to focus on overseas operations in the third quarter by appointing Min Ho-sung as its new CEO. CEO Min oversees the operations of the U.S. and Japanese subsidiaries, as well as overseas clinical trials and global business development (BD). The company also plans to announce the follow-up development plan for “SMUP-IA-01,” its next-generation injectable osteoarthritis treatment, within the year.
A MEDIPOST CO., LTD. official stated, “The third-quarter consolidated financial results largely reflected costs associated with key clinical trials and regulatory preparations to complete the commercialization of Cartistem in the U.S. and Japan,” adding, “We will complete the ongoing Phase 3 clinical trial dosing in the U.S. and preparations for the regulatory filing in Japan without any setbacks, thereby significantly enhancing corporate value and shareholder value.” MEDIPOST CO., LTD. CI (Photo: MEDIPOST CO., LTD.)
LG Innotek has developed an ultra-compact communication module for smart home cameras that integrates Wi-Fi, Bluetooth, and Thread into a single unit. As the company expands its technological capabili…
OTOKI has succeeded in increasing its revenue, driven by strong sales of instant noodles and sauces and rapid overseas growth, despite deteriorating profitability in the domestic market.Ottogi(007310)…
MEDIPOST CO., LTD.(078160)continued its growth trend year-over-year, posting consolidated revenue of 57.5 billion won through the third quarter of this year. “Cartistem,” a stem cell therapy for knee …